Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025)

Guided Therapeutics has disclosed Cash from Operations across 10 years of filings, most recently posting 291000.0 for Q4 2025.

• Cash from Operations for Q4 2025 came in at 291000.0, up 12.35% year-over-year; the trailing twelve-month figure through Dec 2025 was 1068000.0 (up 4.56% YoY), and the FY2025 annual result was 1068000.0, up 4.56% from the prior year.
• Cash from Operations came in at 291000.0 for Q4 2025 at Guided Therapeutics, down from 277000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 159000.0 in Q4 2021 to a low of 739000.0 in Q3 2021.
• The 5-year median for Cash from Operations is 334000.0 (2023), against an average of 350200.0.
• Across the five-year window, Cash from Operations surged 148.04% in 2021 and sank 313.21% in 2022, its largest moves.
• Guided Therapeutics' Cash from Operations stood at 159000.0 in 2021, then slumped by 313.21% to 339000.0 in 2022, then advanced by 0.88% to 336000.0 in 2023, then climbed by 1.19% to 332000.0 in 2024, then grew by 12.35% to 291000.0 in 2025.
• The last three Cash from Operations figures came in at 291000.0 (Q4 2025), 277000.0 (Q3 2025), and 169000.0 (Q2 2025), per Business Quant data.